Island Pharmaceuticals CEO: ISLA-101 Shows Promise in Dengue Fever Fight, Phase 2a next [Video]

Island Pharmaceuticals CEO Dr. David Foster joined Steve Darling from Proactive to share exciting updates on the company’s progress in developing a potential treatment for dengue fever. Foster revealed that Island Pharmaceuticals continues to achieve promising results from testing its ISLA-101 drug candidate, specifically highlighting highly encouraging pharmacokinetics (PK) data obtained from a single ascending dose study. The latest assessment, conducted on 24 subjects, has provided critical PK data essential for understanding how ISLA-101 interacts within the body.

This data is instrumental in establishing appropriate dosing regimens for Island’s planned Phase 2a clinical trial. Notably, the data indicates that even following a single dose, ISLA-101 achieves blood concentrations that have previously been demonstrated to be effective against dengue fever infections. In discussing the significance of these findings, Foster emphasized the urgent need for treatment options for dengue fever, a disease that affects approximately 400 million people annually and is endemic …